We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DEVICEMAKERS SHOULD HELP DEFINE MEDICARE COMPETITIVE BIDDING PROCESS

DEVICEMAKERS SHOULD HELP DEFINE MEDICARE COMPETITIVE BIDDING PROCESS

May 8, 2006

Device manufacturers need to help define how a new proposal on competitive bidding by the Centers for Medicare & Medicaid (CMS) would be implemented, said experts at a recent industry conference hosted by AdvaMed.

"The new rule was designed to harness competition [and] bring value in terms of reduced prices," said Laurence Wilson, director of the CMS' Chronic Care Policy Group, May 3.

The CMS announced a proposed rule April 24 to lower Medicare costs for certain durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) by allowing competitive bidding among manufacturers.

In making its pricing determinations, the agency must factor in the total medical expenditures for a particular type of product or product category, the number of suppliers and the savings potential for Medicare and beneficiaries, Wilson told attendees at the Future of Medicare Policies for Medical Technologies conference.

Under the proposed rule, bidding would be phased in starting in 2007 in 10 of the largest metropolitan statistical areas (MSAs) except New York City, Los Angeles and Chicago. In 2009, the program would expand to 80 of the largest MSAs and into other areas after that.

"That is likely to be as popular a process as base closings," said Wilson. The rule does not identify which 10 metropolitan service areas will be chosen, and it does not establish objective criteria for making those determinations. ()a href="http://www.fdanews.com/ddl/33_19/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing